This inventor holds 2 USPTO granted patents. Top assignees: Rhone-Poulenc Rorer Pharmaceuticals Inc., University of California. Active years: 1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 1994
Title: Innovations of Jeffrey M Dener
Introduction
Jeffrey M Dener is a notable inventor based in King of Prussia, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antithrombotic agents. With a total of two patents to his name, Dener's work focuses on innovative solutions to complex medical challenges.
Latest Patents
Dener's latest patents include "Antithrombotic peptides and pseudopeptides" and "Synthesis of optically active lactones from L-aspartic acid." The first patent relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid, which serve as inhibitors of platelet aggregation and thrombus formation in mammalian blood. This invention also encompasses pharmaceutical compositions that include these compounds and their applications in inhibiting thrombus formation and platelet aggregation in mammals. The second patent describes optically active lactones, which are prepared from L-aspartic acid and can be converted to (+)-pilocarpine and its analogues through various chemical processes.
Career Highlights
Throughout his career, Jeffrey M Dener has worked with prominent organizations, including Rhone-Poulenc Rorer Pharmaceuticals Inc. and the University of California. His experience in these institutions has contributed to his expertise in pharmaceutical research and development.
Collaborations
Dener has collaborated with notable colleagues such as Scott I Klein and Bruce F Molino, further enhancing his contributions to the field of innovation in pharmaceuticals.
Conclusion
Jeffrey M Dener's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile